Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)

• Hlavní autoři: Dong Joo Oh (Autor), Su-Eun Han (Autor), Seung Hee Jeong (Autor), Myung Sook Hong (Autor), Seong Choon Choe (Autor)
• Médium: Kniha
• Vydáno: BMC, 2018-09-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Background Fimasartan (Kanarb; Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea) is a non-protein angiotensin II receptor blocker that selectively blocks the AT1 receptor. No prior large-scale study has investigated the impact of demographics, disease, treatment, and clinical char...